Sulphasalazine retention enemas in ulcerative colitis: a double-blind trial.

Sulphasalazine in ulcerative colitis.

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.

Olsalazine (2 g/day) and sulphasalazine (3 g/day) were compared in a double blind three centre trial in 37 patients presenting with first attack of distal colitis. Sigmoidoscopic appearances, rectal biopsies, and symptom and stool diary records were used to assess benefit and adverse effects. Both groups showed a similar decrease in stool frequency (p less than 0.001). The proportion of unforme...

Controlled Trial of Sulphasalazine in the Treatment of Ulcerative Colitis.

EDITORIAL SYNOPSIS This paper provides further evidence that sulphasalazine is an effective agent in the treatment of mild or moderate colitis. There was a high incidence of gastrointestinal side-effects and one patient developed haemolytic anaemia. Sulphasalazine (salicylazosulphapyridine, Salazo-pyrin, Asulfidine) was first used by Svartz (1942) in the treatment of rheumatoid arthritis. Later...

Sulphasalazine in ulcerative colitis: in memoriam?

Clostridium difficile, sulphasalazine, and ulcerative colitis.

Clostridium difficile has been implicated in the relapse of ulcerative colitis. Controversy exists over this role and its relationship to sulphasalazine exposure. Sixty two of 77 patients with a documented relapse of ulcerative colitis were investigated for the presence of Clostridium difficile, or its toxin, prior to hospitalization. There was a low incidence of detection which was related to ...